Peroxiredoxin 6 Overexpression Attenuates Cisplatin-Induced Apoptosis in Human Ovarian Cancer Cells

REFERENCES

• Chien JR, Aletti G, Bell DA, Keeney GL, Shridhar V, Hartmann LC. Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J Cell Biochem 2007;102:1117–1129.
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265–7279.
   PubMed Web of Science ®Google Scholar
• Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003;22:7512–7523.
   PubMed Web of Science ®Google Scholar
• Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anione by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 1994;203:1175–1180.
   PubMed Web of Science ®Google Scholar
• Park SA, Choi KS, Bang JH, Huh K, Kim SU. Cisplatin-induced apoptotic cell death in mouse hybrid neurons is blocked by antioxidants through suppression of cisplatin-mediated accumulation of p53 but not of Fas/Fas ligand. J Neurochem 2000;75:946–953.
   PubMed Web of Science ®Google Scholar
• Yen HC, Nien CY, Majima HJ, Lee CP, Chen SY, Wei JS, See LC. Increase of lipid peroxidation by cisplatin in WI38 cells but not in SV40-transformed WI38 cells. J Biochem Mol Toxicol 2003;17:39–46.
   PubMed Web of Science ®Google Scholar
• Wozniak A, Drewa G, Wozniak B, Schachtschabel DO, Mila-Kierzenkowska C, Drewa T, Olszewska-Slonina D, Soponska M. The effect of antitumor drugs on oxidative stress in B16 and S91 melanoma cells in vitro. Med Sci Monit 2005;11:BR22–BR29.
   PubMed Web of Science ®Google Scholar
• Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathways. J Phamacol Exp Ther 2005;312:424–431.
   PubMed Web of Science ®Google Scholar
• Fujii J, Ikeda Y. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Report 2002;7:123–130.
   PubMed Web of Science ®Google Scholar
• Hofmann B, Hecht H, Flohe L. Peroxiredoxins. Biol Chem 2002;383:347–364.
   PubMed Web of Science ®Google Scholar
• Rhee SG, Chae HZ, Kim K. Peroxiredoxins: A histological overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 2005;38:1543–1552.
   PubMed Web of Science ®Google Scholar
• Manevich Y, Feinstein SI, Fisher AB. Activation of the antioxidant enzyme 1-cys peroxiredoxin requires glutathionylation mediated by heterodimerization with πGST. Proc Natl Acad Sci USA 2004;101:3780–3785.
   PubMed Web of Science ®Google Scholar
• Ralat LA, Manevich Y, Fisher AB, Colman RF. Direct evidence for the formation of a complex between 1-cys peroxiredoxin and glutathione S-transferase π with activity changes in both enzymes. Biochemistry 2006;45:360–372.
   PubMed Web of Science ®Google Scholar
• Wang X, Phelan SA, Forsman-Semb K, Taylor EF, Petros C, Brown A, Lerner CP, Paigen B. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J Biol Chem 2003;278:25179–25190.
   PubMed Web of Science ®Google Scholar
• Kaihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003;9:3418–3424.
   PubMed Web of Science ®Google Scholar
• Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, Saily M, Kinnula V. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 2004;111:514–521.
   PubMed Web of Science ®Google Scholar
• Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol 2006;175:1512–1516.
   PubMed Web of Science ®Google Scholar
• Chung YM, Yoo YD, Park JK, Kim YT, Kim HJ. Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res 2001;21:1129–1133.
   PubMed Web of Science ®Google Scholar
• Park SH, Chung YM, Lee YS, Kim HJ, Kim JS, Chae HZ, Yoo YD. Antisense of human peroxiredoxin II enhances radiation-induced cell death. Clin Cancer Res 2000;6:4915–4920.
   PubMed Web of Science ®Google Scholar
• Yoo YD, Chung YM, Park JK, Ahn CM, Kim SK, Kim HJ. Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death. Exp Mol Med 2002;34:273–277.
   PubMed Web of Science ®Google Scholar
• Zhang B, Su Y, Ai G, Wang Y, Wang T, Wang F. Involvement of peroxiredoxin I in protecting cells from radiation-induced death. J Radiat Res 2005;46:305–312.
   PubMed Web of Science ®Google Scholar
• Cho JM, Manandhar S, Lee HR, Park HM, Kwak MK. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: Implication to cancer cell resistance. Cancer Lett 2008;260:96–108.
   PubMed Web of Science ®Google Scholar
• Manevich Y, Sweitzer T, Pak JH, Feinstein SI, Muzykantov V, Fisher AB. 1-Cys peroxiredoxin overexpression protects cells against phospholipids peroxidation-mediated membrane damage. Proc Natl Acad Sci USA 2002;99:11599–11604.
   PubMed Web of Science ®Google Scholar
• Sinha P, Poland J, Kohl S, Schnolzer M, Helmbach H, Hutter G, Lage H, Schadendorf D. Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis 2003;24:2386–2404.
   PubMed Web of Science ®Google Scholar
• Castagna A, Antonioli P, Astner H, Hamdan M, Righetti SC, Perego P, Zunino F, Righetti PG. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004;4:3246–3267.
   PubMed Web of Science ®Google Scholar
• Muldoon LL, Walker-Rosenfeld SL, Hale C, Purcell SE, Bennett LC, Neuwelt EA. Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants. J Pharmacol Exp Ther 2001;296:797–805.
   PubMed Web of Science ®Google Scholar
• Manevich Y, Fisher AB. Peroxiredoxin 6, 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic Biol Med 2005;38:1422–1432.
   PubMed Web of Science ®Google Scholar
• Kim HS, Manevich Y, Feinstein, Pak JH, Ho YS, Fisher AB. Induction of 1-cys peroxiredoxin expression by oxidative stress in lung epithelial cells. Am J Physiol Lung Mol Physiol 2003;285: L363–L369.
   PubMed Web of Science ®Google Scholar
• Gallagher BM, Phelan SA. Investigating transcriptional regulation of Prdx6 in mouse liver cells. Free Radic Biol Med 2007;42: 1270–1277.
   PubMed Web of Science ®Google Scholar
• Tchah H, Kim MJ, Kim T, Choi H, Kim JY, Kim MJ, Pak JH. Regulation of 1-cys peroxiredoxin expression in the process of stromal wound healing after photorefraxtive keratechtomy. Invest Ophthalmol Vis Sci 2005;46:2396–2403.
   PubMedGoogle Scholar
• Kim SY, Jo HY, Kim MH, Cha YY, Choi SW, Shim JH, Kim TJ, Lee KY. H2O2-dependent hyperoxidation of peroxiredoxin 6 (Prdx6) plays a role in cellular toxicity via up-regulation of iPLA2 activity. J Biol Chem 2008;283:33563–33568.
   PubMed Web of Science ®Google Scholar
• Pak JH, Kim TI, Kim MJ, Kim JY, Choi HJ, Kim SA, Tchah H. Reduced expression of 1-cys peroxiredoxin in oxidative stress-induced cataracts. Exp Eye Res 2006;82:899–906.
   PubMed Web of Science ®Google Scholar
• Fatma N, Kubo E, Sen M, Agarwal N, Thoreson WB, Camras CB, Singh DP. Peroxiredoxin 6 delivery attenuates TNF-α and glutamate-induced retinal ganglion cell death by limiting ROS levels and maintaining Ca2+ homeostasis. Brain Res 2008;1233: 63–78.
   PubMed Web of Science ®Google Scholar
• Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 2002;196:316–323.
   PubMed Web of Science ®Google Scholar
• Li DQ, Wang L, Fei F, Hou YF, Luo JM, Chen W, Zeng R, Wu J, Lu JS, Di GH, Ou ZL, Xia QC, Shen ZZ, Shao ZM. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimentional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 2006;6:3352–3368.
   PubMed Web of Science ®Google Scholar
• Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 2007;9:R76.
   PubMed Web of Science ®Google Scholar